-
公开(公告)号:US20100240679A1
公开(公告)日:2010-09-23
申请号:US12789892
申请日:2010-05-28
申请人: Richard Sedrani , Juergen Klaus Maibaum , Werner Breitenstein , Holger Sellner , Claus Ehrhardt , Nils Ostermann
发明人: Richard Sedrani , Juergen Klaus Maibaum , Werner Breitenstein , Holger Sellner , Claus Ehrhardt , Nils Ostermann
IPC分类号: A61K31/506 , C07D211/94 , A61K31/451 , A61K31/4525 , A61K31/4545 , A61K31/4535 , A61K31/454 , C07D239/26 , A61P3/00 , A61P13/12 , A61P9/00 , A61P27/06 , A61P25/28 , A61P25/22
CPC分类号: C07D401/10 , C07D211/42 , C07D405/04 , C07D409/10
摘要: Compounds of the present invention having the formula exhibit inhibitory activity on the natural enzyme renin. Thus, compounds of formula (I) may be employed for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders.
摘要翻译: 具有下式的本发明化合物对天然酶肾素表现出抑制活性。 因此,式(I)化合物可用于治疗高血压,动脉粥样硬化,不稳定冠状动脉综合征,充血性心力衰竭,心脏肥大,心脏纤维化,心肌梗塞后梗死,冠状动脉综合征不稳定,舒张功能障碍,慢性肾脏疾病,肝纤维化, 糖尿病引起的并发症如肾病,血管病变和神经病变,冠状血管疾病,血管成形术后再狭窄,眼内压升高,青光眼,异常血管生长,醛固酮增多症,认知障碍,阿尔茨海默病,痴呆,焦虑状态和认知障碍。
-
公开(公告)号:US20100048539A1
公开(公告)日:2010-02-25
申请号:US12513498
申请日:2007-11-02
申请人: Donatella Chianelli , Xiaolin Li , Xiaodong Liu , Jon Loren , Valentina Molteni , Juliet Nabakka , Laszlo Revesz , Lawrence B. Perez , Clinton Brooks , Wojciech Wrona , Paul William Manley , Werner Breitenstein
发明人: Donatella Chianelli , Xiaolin Li , Xiaodong Liu , Jon Loren , Valentina Molteni , Juliet Nabakka , Laszlo Revesz , Lawrence B. Perez , Clinton Brooks , Wojciech Wrona , Paul William Manley , Werner Breitenstein
IPC分类号: A61K31/506 , C07D401/14 , C07D413/14 , C07D405/14 , A61K31/5377 , A61K31/538 , A61K31/55 , C12N5/00 , A61P35/00 , A61P37/00 , A61P3/00 , A61P25/00 , A61P9/00 , A61P37/08
CPC分类号: C07D401/14 , C07D401/04 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14
摘要: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to beat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of c-kit, PDGFRα and PDGFRβ kinases. Formula (I).
摘要翻译: 本发明提供了一类新颖的化合物,包含这些化合物的药物组合物和使用这些化合物来击败或预防与异常或失调的激酶活性相关的疾病或病症的方法,特别是涉及c-kit,PDGFRα异常活化的疾病或病症,以及 PDGFR&bgr 激酶。 式(I)。
-
公开(公告)号:US20070078164A1
公开(公告)日:2007-04-05
申请号:US10580296
申请日:2004-11-25
申请人: Richard Sedrani , Juergen-Klaus Maibaum , Werner Breitenstein , Holger Sellner , Claus Ehrhardt , Nils Ostermann
发明人: Richard Sedrani , Juergen-Klaus Maibaum , Werner Breitenstein , Holger Sellner , Claus Ehrhardt , Nils Ostermann
IPC分类号: A61K31/454 , C07D401/02
CPC分类号: C07D401/10 , C07D211/42 , C07D405/04 , C07D409/10
摘要: Compounds of the present invention having the formula exhibit inhibitory activity on the natural enzyme renin. Thus, compounds of formula (I) may be employed for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders.
摘要翻译: 具有下式的本发明化合物对天然酶肾素表现出抑制活性。 因此,式(I)化合物可用于治疗高血压,动脉粥样硬化,不稳定冠状动脉综合征,充血性心力衰竭,心脏肥大,心脏纤维化,心肌梗塞后梗死,冠状动脉综合征不稳定,舒张功能障碍,慢性肾脏疾病,肝纤维化, 糖尿病引起的并发症如肾病,血管病变和神经病变,冠状血管疾病,血管成形术后再狭窄,眼内压升高,青光眼,异常血管生长,醛固酮增多症,认知障碍,阿尔茨海默病,痴呆,焦虑状态和认知障碍。
-
公开(公告)号:US20060167015A1
公开(公告)日:2006-07-27
申请号:US10520359
申请日:2003-07-04
申请人: Werner Breitenstein , Pascal Furet , Sandra Jacob , Paul Manley
发明人: Werner Breitenstein , Pascal Furet , Sandra Jacob , Paul Manley
IPC分类号: A61K31/506 , C07D403/14
CPC分类号: C07D401/14 , C07D405/14
摘要: The invention relates to compounds of formula wherein the substituents R1, R2 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, especially a neoplastic disease, in particular leukaemia, and a method for the treatment of such a disease.
-
公开(公告)号:US07081532B2
公开(公告)日:2006-07-25
申请号:US10363841
申请日:2001-09-11
申请人: Hans M Buerger , Giorgio Caravatti , Juerg Zimmermann , Paul W Manley , Werner Breitenstein , Margaret A Cudd
发明人: Hans M Buerger , Giorgio Caravatti , Juerg Zimmermann , Paul W Manley , Werner Breitenstein , Margaret A Cudd
IPC分类号: C07D403/10
CPC分类号: C07D401/04 , A61K31/506
摘要: The invention relates to N-phenyl-2-pyrimidine-amine derivatives of formula (I) wherein the substituents are defined as in the description, to processes for the preparation thereof, to medicaments comprising those compounds, and the use thereof in the preparation of pharmaceutical compositions for the therapeutic treatment of warm-blooded animals, including humans.
摘要翻译: 本发明涉及式(I)的N-苯基-2-嘧啶 - 胺衍生物,其中取代基如说明书中所定义,其制备方法,含有这些化合物的药物及其在制备 用于治疗温血动物(包括人)的药物组合物。
-
公开(公告)号:US20060142577A1
公开(公告)日:2006-06-29
申请号:US10528913
申请日:2003-09-26
申请人: Paul Manley , Werner Breitenstein , Sandra Jacob , Pascal Furet
发明人: Paul Manley , Werner Breitenstein , Sandra Jacob , Pascal Furet
IPC分类号: A61K31/506 , C07D403/14
CPC分类号: C07D401/04
摘要: The invention relates to novel substituted N-(3-benzoylaminophenyl)-4-pyridyl-2-pyrimidinamine derivatives, processes for the preparation thereof, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, especially a neoplastic disease, and a method for the treatment of such a disease.
摘要翻译: 本发明涉及新的取代的N-(3-苯甲酰氨基苯基)-4-吡啶基-2-嘧啶胺衍生物,其制备方法,含有它们的药物组合物,其用途任选与一种或多种其它药物活性化合物组合用于 治疗对抑制蛋白激酶活性,特别是肿瘤性疾病作出反应的疾病,以及治疗这种疾病的方法。
-
公开(公告)号:US4808572A
公开(公告)日:1989-02-28
申请号:US936671
申请日:1986-12-01
IPC分类号: A61K31/16 , A61K31/165 , A61K31/19 , A61K31/195 , A61K31/215 , A61K31/22 , A61K31/23 , A61K38/00 , A61K45/00 , A61P11/00 , A61P29/00 , A61P37/08 , A61P43/00 , C07C67/00 , C07C313/00 , C07C321/18 , C07C323/00 , C07C323/52 , C07C323/58 , C07C323/59 , C07C323/60 , C07K1/113 , C07K5/02 , C07K5/06 , C07C149/243
CPC分类号: C07K5/0606 , A61K31/19 , A61K31/215 , C07C323/00 , A61K38/00
摘要: Novel asymmetric thioethers of the formula ##STR1## in which the general symbols have the following meanings: a is an integer of from 1 to 7,R.sup.o represents hydrogen or C.sub.1-7 -alkanoyl,R.sup.1 represents C.sub.1-3 -alkyl which may be substituted at the terminal carbon atom by a free or acylated hydroxy group, by a halogen atom having an atomic number of at most 17, or by methoxy, or represents C.sub.1-3 -perfluoroalkyl,R.sup.2 represents an optionally unsaturated aliphatic radical having from 5 to 15 carbon atoms,A represents ethylene or alternatively, if R.sup.1 represents a halogenated radical and/or B represents phenylene or ethylene, a single bond or vinylene,B represents a single bond, ethynylene or phenylene,R.sup.3 represents hydroxy, C.sub.1-7 -alkoxy or an optionally substituted amino group, and--X-- represents a single bond, a methylene group of an optionally N-acylated primary aminomethylene group,and their salts are active as leucotriene antagonists since they eliminate the contractions of smooth muscles brought about by leucotrienes, and are therefore suitable for the treatment of allergic, especially asthmatic, conditions.
摘要翻译: 式(I)的新型不对称硫醚,其中通式具有以下含义:a为1至7的整数,R 4表示氢或C 1-7 - 烷酰基,R 1表示C 1-3 - 烷基, 可以在末端碳原子上被游离或酰化的羟基,原子数至多为17的卤素原子或甲氧基取代,或表示C1-3-全氟烷基,R2表示任选不饱和的脂肪族基,其具有 5至15个碳原子,A代表乙烯,或者,如果R1代表卤代基,和/或B代表亚苯基或亚乙基,则单键或亚乙烯基,B代表单键,亚乙炔基或亚苯基,R3代表羟基,C1-7 - 烷氧基或任选取代的氨基,-X-表示单键,任选N-酰化的伯氨基亚甲基的亚甲基,并且它们的盐作为白三烯拮抗剂是有活性的,因为它们消除平滑肌的收缩b 由白细胞三烯生成,因此适用于治疗过敏性疾病,特别是哮喘病症。
-
公开(公告)号:US4785004A
公开(公告)日:1988-11-15
申请号:US941676
申请日:1986-12-15
IPC分类号: C07D215/54 , C07D311/24 , C07C149/40 , A61K31/235
CPC分类号: C07D311/24 , C07D215/54
摘要: Novel asymmetric thioethers of the formula ##STR1## in which the general symbols have the following meanings: R.sup.0 represents hydrogen or C.sub.1-7 -alkanoyl,R.sup.1 represents C.sub.1-3 -alkyl which may be substituted by one or more halogen atoms having an atomic number of at most 17,R.sup.2 represents an aliphatic radical having from 5 to 15 carbon atoms,A represents ethylene, a single bond or vinylene,B.sup.1 represents C.sub.1-7 -alkylene or phenylene,B.sup.2 represents a single bond, ethylene or phenylene, andM represents an aromatic radical of the partial formula ##STR2## in which the symbols have the following meanings: R.sup.3 represents hydrogen or C.sub.1-4 -alkyl,X represents NH, O, S or if R.sup.4 represents hydrogen, a single bond,one of the symbols R.sup.4 and R.sup.5 represents hydrogen and the other represents the group --CO--R.sup.6, orR.sup.4 and R.sup.5 together represent the radical --CO--C(R.sup.6).dbd.C(R.sup.7)--or--CO--C(R.sup.7).dbd.C(R.sup.6)--orR.sup.4 R.sup.5, together with X, represent the radical --N.dbd.C(R.sup.8)--C(R.sup.6).dbd.CH--,in whichR.sup.6 represents --(CH.sub.2).sub.b --COOR.sup.3 (in which b=0 to 2)R.sup.7 represents hydrogen or C.sub.1-4 -alkyl andR.sup.8 represents hydrogen, methyl, mythoxy or halogen,and their salts are active as leucotriene antagonists since they eliminate the contractions of smooth muscles brought about by leucotrienes, and are therefore suitable for the treatment of allergic, especially asthmatic, conditions.
摘要翻译: 式(I)的新颖的不对称硫醚,其中通式符号具有以下含义:R 0表示氢或C 1-7 - 烷酰基,R 1表示可以被一个或多个具有 原子数最多为17,R 2表示具有5至15个碳原子的脂族基团,A表示乙烯,单键或亚乙烯基,B1表示C1-7 - 亚烷基或亚苯基,B2表示单键,乙烯或亚苯基 ,M表示部分结构式(M)的芳族基团,其中符号具有以下含义:R 3表示氢或C 1-4 - 烷基,X表示NH,O,S或如果R 4表示氢,则 单键,R4和R5之一表示氢,另一个表示-CO-R6基团,或R4和R5一起代表基团-CO-C(R6)= C(R7)-OR-CO-C( R7)= C(R6) - 或R4R5与X一起代表基团-N = C(R8)-C(R6)= CH-,其中R6表示 - (CH2)b-COOR3(其中b = 0至2)R7表示氢或C1-4烷基,R8表示氢,甲基,乙氧基或卤素,并且它们的盐作为白三烯拮抗剂是有活性的,因为它们消除了由白三烯引起的平滑肌的收缩,因此适用于 治疗过敏,特别是哮喘,病情。
-
公开(公告)号:US4644069A
公开(公告)日:1987-02-17
申请号:US762755
申请日:1985-08-06
IPC分类号: C07D307/60 , C07C51/56 , C07C51/567 , C07D401/04 , C07D417/04
CPC分类号: C07C51/56 , C07C51/567
摘要: The reaction of maleic acid, fumaric acid and/or maleic anhydride in the presence of N-acylated heterocyclic amidines and at elevated temperature affords dimethylmaleic anhydride in good yield. Catalytic amounts of the amidine employed are sufficient for said reaction.
摘要翻译: 马来酸,富马酸和/或马来酸酐在N-酰化杂环脒存在下并在升高的温度下的反应得到了良好的收率的二甲基马来酸酐。 所用的脒的催化量足以用于所述反应。
-
公开(公告)号:US20130012704A1
公开(公告)日:2013-01-10
申请号:US13617881
申请日:2012-09-14
申请人: Qiang DING , Nathanael Schiander GRAY , Bing LI , Yi LIU , Taebo SIM , Tetsuo UNO , Guobao ZHANG , Carole Pissot Soldermann , Werner BREITENSTEIN , Guido BOLD , Giorgio CARAVATTI , Pascal FURET , Vito GUAGNANO , Marc LANG , Paul W. MANLEY , Joseph SCHOEPFER , Carsten SPANKA
发明人: Qiang DING , Nathanael Schiander GRAY , Bing LI , Yi LIU , Taebo SIM , Tetsuo UNO , Guobao ZHANG , Carole Pissot Soldermann , Werner BREITENSTEIN , Guido BOLD , Giorgio CARAVATTI , Pascal FURET , Vito GUAGNANO , Marc LANG , Paul W. MANLEY , Joseph SCHOEPFER , Carsten SPANKA
IPC分类号: C07D403/12 , C07C265/12 , C07D413/12 , C07D405/12 , C07D409/14 , C07D401/12 , C07D401/14 , C07C217/84 , C07D239/48
CPC分类号: C07D239/48 , C07D251/48 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12
摘要: The invention relates to compounds of formula (I) wherein the substituents X1, R1, R2, R3 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, and a method for the treatment of such a disease.
-
-
-
-
-
-
-
-
-